Welcome to ColoradoLifeScience.com
ColoradoLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Colorado's BioHistory
Why is there a biotechnology industry in Colorado? Will the industry continue
to grow in Colorado? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Colorado BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Colorado.
More CO BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- Primovist(R) approved in the U.S. for the detection and characterization of liver lesions The U.S. Food and Drug Administration has approved Bayer Schering Pharma’s magnetic resonance imaging contrast agent Primovist(R) (gadoxetate disodium) for the detection and characterization of liver lesions in adults with known or suspected focal liver disease.
Bayer July 08, 2008
- FDA grants Invitrogen premarket approval of breast cancer test Invitrogen announced it has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light(R) HER2 CISH Kit, indicated as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin(R)) treatment is being considered.
Invitrogen Corporation July 08, 2008
- Herculean device for molecular mysteries A privately financed team of scientists and engineers is nearing completion of a special-purpose supercomputer intended to offer more than a thousandfold increase in performance for complex molecular simulations.
The New York Times July 08, 2008 John Markoff
- Wyeth applauds inclusion of the PCV7 vaccine in countries' immunization schedules Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their decisions to routinely immunize infants and young children against pneumococcal disease by adding PREVENAR(TM) PCV7 to their national immunization programs.
Wyeth July 08, 2008
- Lilly to acquire SGX Pharmaceuticals Eli Lilly and Company and SGX Pharmaceuticals announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction.
Eli Lilly and Company July 08, 2008
More... | Submit News Release | National News
|